265 related articles for article (PubMed ID: 34293540)
1. Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients.
Megías-Vericat JE; Bonanad S; Haya S; Cid AR; Marqués MR; Ferrada A; Monte-Boquet E; Pérez-Alenda S; Bosch P; Querol-Giner F; Poveda JL
Thromb Res; 2021 Sep; 205():99-105. PubMed ID: 34293540
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
Rakmanotham A; Moonla C; Sosothikul D
Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
[TBL] [Abstract][Full Text] [Related]
3. Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis.
Srichumpuang C; Rakmanotham A; Moonla C; Sosothikul D
Orphanet J Rare Dis; 2024 Mar; 19(1):135. PubMed ID: 38532451
[TBL] [Abstract][Full Text] [Related]
4. Real pandemic world results of pharmacokinetic-tailored personalized prophylaxis of bleeds in Polish children and adolescents with severe hemophilia A.
Urasiński T; Paczóska K; Badowska W; Bobrowska H; Dakowicz Ł; Dobaczewski G; Latos-Grażyńska E; Karolczyk G; Klukowska A; Kołtan A; Wojdalska M; Łaguna P; Niedźwiedzki M; Pietrys D; Radoń-Proskura J; Radwańska M; Rurańska I; Szczepański T; Wasiński D; Woźnica-Karczmarz I; Zielezińska K; Królak A; Ociepa T
Front Pediatr; 2023; 11():1084539. PubMed ID: 36911027
[TBL] [Abstract][Full Text] [Related]
5. Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A.
Megías-Vericat JE; Bonanad S; Haya S; Cid AR; Marqués MR; Monte E; Pérez-Alenda S; Bosch P; Querol F; Poveda JL
Thromb Res; 2019 Feb; 174():151-162. PubMed ID: 30634166
[TBL] [Abstract][Full Text] [Related]
6. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.
Neufeld EJ; Sidonio RF; O'Day K; Runken MC; Meyer K; Spears J
J Med Econ; 2018 Aug; 21(8):762-769. PubMed ID: 29681200
[TBL] [Abstract][Full Text] [Related]
7. Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS.
Lalezari S; Martinowitz U; Windyga J; Enriquez MM; Delesen H; Schwartz L; Scharrer I
Haemophilia; 2014 Jan; 20(1):e15-22. PubMed ID: 24252058
[TBL] [Abstract][Full Text] [Related]
8. Improvement in clinical outcomes and replacement factor VIII use in patients with haemophilia A after factor VIII pharmacokinetic-guided prophylaxis based on Bayesian models with myPKFiT
Mingot-Castellano ME; Parra R; Núñez R; Martorell M
Haemophilia; 2018 Sep; 24(5):e338-e343. PubMed ID: 30028549
[TBL] [Abstract][Full Text] [Related]
9. More than a decade of international experience with a pdFVIII/VWF concentrate in immune tolerance.
Santagostino E
Haemophilia; 2013 Jan; 19 Suppl 1():8-11. PubMed ID: 23278994
[TBL] [Abstract][Full Text] [Related]
10. Switch to pdVWF:pdFVIII concentrate for prophylaxis in a paediatric patient with Type 3 von Willebrand disease: a case report.
Berger C; Thouvenin S; Montmartin A; Noyel P; Legendre C; Tardy-Poncet B
Hematology; 2023 Dec; 28(1):2186332. PubMed ID: 36892261
[TBL] [Abstract][Full Text] [Related]
11. Impact of capacity-limited binding on recombinant factor VIII and von Willebrand factor pharmacokinetics in hemophilia A rats.
Vargas Christensen I; Loftager M; Rode F; Mørck Nielsen H; Kreilgaard M; Larsen MS
J Thromb Haemost; 2019 Jun; 17(6):964-974. PubMed ID: 30924607
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic study of Kovaltry in thirty-five pediatric patients aged <12 years with severe hemophilia A.
Huang K; Zhen Y; Li G; Wu X; Wu R; Chen Z
Haemophilia; 2021 May; 27(3):e340-e346. PubMed ID: 33645868
[TBL] [Abstract][Full Text] [Related]
13. Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study.
Zourikian N; Merlen C; Bonnefoy A; St-Louis J; Rivard GE
Haemophilia; 2016 May; 22(3):e177-83. PubMed ID: 26988074
[TBL] [Abstract][Full Text] [Related]
14. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
Mannucci PM; Shi Q; Bonanad S; Klamroth R
Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
[TBL] [Abstract][Full Text] [Related]
15. Non-additive effect on thrombin generation when a plasma-derived factor VIII/von Willebrand factor (FVIII/VWF) is combined with emicizumab in vitro.
Bravo MI; Raventós A; Pérez A; Costa M; Willis T
J Thromb Haemost; 2020 Aug; 18(8):1934-1939. PubMed ID: 32379931
[TBL] [Abstract][Full Text] [Related]
16. Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients.
Swystun LL; Ogiwara K; Rawley O; Brown C; Georgescu I; Hopman W; Labarque V; Male C; Thom K; Blanchette VS; Carcao MD; Lillicrap D
Blood; 2019 Sep; 134(11):880-891. PubMed ID: 31350267
[TBL] [Abstract][Full Text] [Related]
17. A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients.
Yu JK; Iorio A; Edginton AN
Thromb Res; 2020 Dec; 196():550-558. PubMed ID: 33157394
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study.
Chen ZP; Li PJ; Li G; Tang L; Zhen YZ; Wu XY; Cheng XL; Luke KH; Blanchette VS; Poon MC; Ding QL; Wu RH
Chin Med J (Engl); 2018 Aug; 131(15):1780-1785. PubMed ID: 29848837
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Individualized Preventive Treatment of Patients with Severe Hemophilia A Guided by Multiple Clinical Parameters and Pharmacokinetics.
Wang Y; Yang Q; Zheng L; Wang X; Jiang W; Lu L; Yan L; Zhang M; Chen L
Acta Haematol; 2022; 145(4):354-361. PubMed ID: 34879368
[TBL] [Abstract][Full Text] [Related]
20. Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors.
Bravo MI; Da Rocha-Souto B; Grancha S; Jorquera JI
Haemophilia; 2014 Nov; 20(6):905-11. PubMed ID: 25156825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
